Preamble
Asymptomatic severe aortic stenosis remains a tricky and delicate decsion making process for the cardiologists. A fine balance of clinical assessment and indication as well as the academic and also peer prssure for an immedaute fix, that now includes non surgical TAVR.In fact with the arrival of TAVI , the decsion making has become much more complex .It is an invisible stastical abttle between succes , failure and complication rate vs sitting idle and watchfuly waiting.
Proponents of early surgery are on the edge, backed by the results of trials like RECOVERY and AVATAR .TAVI guys are smiling .Ofcourse , they can argue that timely intervention preempts irreversible myocardial fibrosis, sudden cardiac death, and failure.
Natural history of Aortic stenosis : The most popular illustration published in 1968 still surviving the time , how accurate is it, in 2026 ? Learn yourself : Link to the original article and the new one ( Ross J Jr, Braunwald E.Circulation. 1968 Marcoff L et al Curr Cardiol Rep. 2023 25.)
The conservative* “wait-and-watch” approach cardiologists need not feel guilty or looked down upon. They rely on stringent clinical and echocardiographic surveillance. This strategy protects asymptomatic individuals from the immediate risks of perioperative mortality, prosthetic valve degeneration, and lifelong anticoagulation. *Conserves what ? (Valve, life , money ?)
Amidst this difficult debate, the landmark EVOLVED study from Scotland UK, stands out among the crowd. By utilizing cardiac MRI to detect midwall fibrosis, EVOLVED demonstrated that routine early surgery based strictly on statistical thresholds does not universally superioritize outcomes over high-quality surveillance. Instead, it highlighted that meticulous clinical acumen and symptom tracking remain paramount.
Final message
Lack of data appear bad science , but datas can be deadly too. Some how , data will always push for early intervention . EVOLVED trial is unique .It proves that clinical acumen-based indications will prevail over technology . It sort of reminds us the principle of primum non nocere (first, do no harm), every patient should earn their procedure due to developing meaningful symptoms, rather than hospitals trying to earn out of patients.
Reference
- RECOVERY Trial:
Kang DH, Park SJ, Lee SA, Kim YJ, Kim DH, Kim HK, et al. Early surgery or conservative care for asymptomatic aortic stenosis. N Engl J Med. 2020 Jan 9;382(2):111-119. doi: 10.1056/NEJMoa1909883. PubMed PMID: 31733181. - AVATAR Trial:
Banovic M, Putnik S, Penicka M, Doros G, Deja MA, Kockova R, et al. Aortic valve replacement versus conservative treatment in asymptomatic severe aortic stenosis: the AVATAR trial. Circulation. 2022 Mar 15;145(11):797-808. doi: 10.1161/CIRCULATIONAHA.121.057639. PubMed PMID: 34779220. - EARLY TAVR Trial:
Généreux P, Piazza N, Alu MC, Nazif TM, Hahn RT, Pibarot P, et al. Transcatheter aortic-valve replacement for asymptomatic severe aortic stenosis. N Engl J Med. 2024 Oct 28;391(22):2111-2122. doi: 10.1056/NEJMoa2405880. PubMed PMID: 39466903. - EVOLVED Trial:
Loganath K, Greenwood JP, Plein S, McCann GP, Berry C, McConnachie A, et al. Early intervention in patients with asymptomatic severe aortic stenosis and myocardial fibrosis: the EVOLVED randomized clinical trial. JAMA. 2024 Oct 28;332(20):1741-1750. doi: 10.1001/jama.2024.22557. PubMed PMID: 39466640.
